Are Circulating Cytokines Reliable Biomarkers for Amyotrophic Lateral Sclerosis?

Int J Mol Sci. 2019 Jun 5;20(11):2759. doi: 10.3390/ijms20112759.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that has no effective treatment. The lack of any specific biomarker that can help in the diagnosis or prognosis of ALS has made the identification of biomarkers an urgent challenge. Multiple panels have shown alterations in levels of numerous cytokines in ALS, supporting the contribution of neuroinflammation to the progressive motor neuron loss. However, none of them is fully sensitive and specific enough to become a universal biomarker for ALS. This review gathers the numerous circulating cytokines that have been found dysregulated in both ALS animal models and patients. Particularly, it highlights the opposing results found in the literature to date, and points out another potential application of inflammatory cytokines as therapeutic targets.

Keywords: amyotrophic lateral sclerosis; biomarkers; blood; cerebrospinal fluid; cytokines; diagnosis; inflammation; plasma; prognosis; serum.

Publication types

  • Review

MeSH terms

  • Amyotrophic Lateral Sclerosis / blood*
  • Amyotrophic Lateral Sclerosis / immunology
  • Amyotrophic Lateral Sclerosis / therapy
  • Animals
  • Biomarkers / blood*
  • Body Fluids / metabolism
  • Cytokines / blood*
  • Humans
  • Immune System / metabolism
  • Inflammation / pathology

Substances

  • Biomarkers
  • Cytokines